PKD1 uORF Suppression to Raise PC1 in Polycystic Kidney Disease

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for autosomal dominant polycystic kidney disease (ADPKD) and polycystic liver disease (PCLD) are limited by significant side effects and lack of efficacy, with no FDA-approved therapies for liver cysts, and existing methods to increase polycystin-1 (PC1) expression have unpredictable off-target effects.

Innovation Solution

Administering compounds that suppress the translation of upstream open reading frames (uORFs) in the PKD1 gene, such as CRISPR components or antisense oligonucleotides (ASOs), to increase PC1 expression and prevent cyst formation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If tolvaptan is administered to treat ADPKD, then kidney function delay is achieved, but significant side effects occur including polyuria and hepatic injury

Engineering Contradiction:

Improvekidney function delayVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and targets the specific molecular mechanism (uORF translation) that regulates PKD1 expression, separating the therapeutic effect from the side effects of existing drugs like tolvaptan. By using ASOs to specifically suppress uORF translation, the treatment achieves kidney protection without the polyuria and hepatic injury caused by tolvaptan.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent introduces antisense oligonucleotides (ASOs) as an intermediary molecule that binds to uORF mRNA to prevent its translation. This intermediary approach allows precise control of PKD1 expression through uORF suppression without the direct side effects of tolvaptan on kidney tubules and liver.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If existing methods to increase PC1 expression are used, then polycystic disease progression is slowed, but unpredictable off-target effects occur

Engineering Contradiction:

Improvepolycystic disease progression slowdownVSAvoidoff-target effects

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The patent applies local quality by targeting the specific uORF regions within the PKD1 mRNA transcript. The ASOs are designed to bind specifically to uORF1 and/or uORF2 sequences, suppressing translation only at these localized regions while leaving the rest of the mRNA intact. This precise local targeting increases PC1 expression without unpredictable off-target effects.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent replaces the non-specific mechanical approach of general PC1 overexpression with a molecular-level precision approach using ASO-uORF binding. Instead of broadly increasing PC1 expression through undefined mechanisms, the invention uses sequence-specific ASO binding to uORFs to precisely control translation initiation, eliminating off-target effects.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Measurement precision

If CRISPR components or ASOs are used to suppress uORF translation, then PC1 expression is increased with high specificity, but translation suppression mechanism complexity increases

Engineering Contradiction:

Improvetranslation suppression specificityVSAvoidtranslation suppression mechanism

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent uses antisense oligonucleotides (ASOs) as disposable, short-lived therapeutic agents that temporarily suppress uORF translation without requiring permanent genomic modification. The ASOs are administered systemically and degraded naturally after performing their function, providing high specificity through sequence complementarity while avoiding the complexity of permanent CRISPR-Cas9 genome editing systems.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enhances PC1 protein levels, potentially preventing or ameliorating cyst development in ADPKD and PCLD with high specificity, avoiding the side effects of existing treatments.

Implementation Method 1

CRISPR components that disrupt the genomic DNA sequence that encoding the first uORF, the second uORF, the third uORF, and/or a fourth uORF

Methodology Applied

Scientific EffectCRISPR gene editing:

Implementation Method 2

an antisense oligonucleotide (ASO) that blocks the translation of the first uORF, the second uORF, the third uORF, and/or a fourth uORF

Methodology Applied

Scientific EffectAntisense oligonucleotide binding:

Data Source

PatentUS20250339561A1Methods of treating, ameliorating and/or preventing polycystic kidney disease and polycystic liver disease

Publication Date: 2025.11.06 YALE UNIVERSITY

AI summary

Described herein is a method of ameliorating and/or preventing autosomal dominant polycystic kidney disease (ADPKD) or a polycystic liver disease (PCLD) in a subject in need thereof. The method includes administering to the subject an effective amount of a compound that suppresses the translation of the first upstream open reading frame (uORF), the second uORF, the third uORF and/or the fourth uORF of the PKD1 gene.